China's largest maker of tissue paper, sanitary napkins and disposable diapers.
China's largest maker of tissue paper, sanitary napkins and disposable diapers.
Sells sanitary and tissue products mainly through supermarkets and online platforms, spending heavily on advertising and promotions. Pulp is its main raw material, so costs swing with pulp prices. The founding families remain significant shareholders.
In one line: China's Kimberly-Clark.
Moat: narrow (brand, scale, distribution). Long-established Hengan/Anerle brands with broad national distribution in a largely commoditized category.
Headquarters: Fujian, China · Founded: 1985 · Employees: 23,000
Size Hengan Int'l (1044.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $3.27B, the 319th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$22.22 on 18 Nov 2026.
Performance Over six months the shares fell 12.0%, against +6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +4.3%); the operating margin is 11.2% (peer median 11.2%).
Valuation It trades at 9.1× forward earnings against a peer median of 23.1× (2nd cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.2 points above its cost of capital (6.2% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$25.0B | HK$25.0B | HK$24.6B | HK$26.3B | HK$26.3B |
| Revenue growth | — | +2% | -6% | 0% | — |
| Gross profit | HK$8.80B | HK$8.43B | HK$7.91B | HK$8.82B | HK$8.90B |
| EBITDA | HK$3.97B | HK$3.72B | HK$3.39B | HK$4.10B | HK$4.26B |
| Net income | HK$2.70B | HK$2.75B | HK$2.49B | HK$3.09B | HK$2.24B |
| Free cash flow | HK$1.69B | HK$2.53B | HK$2.08B | HK$3.12B | HK$3.27B |
| Capital expenditure | HK$1.15B | HK$1.14B | HK$1.68B | HK$1.68B | HK$1.45B |
| Total debt | n/a | HK$17.6B | HK$14.0B | HK$15.7B | HK$19.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hengan Int'l 1044.HK | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% |
| Softcare 2698.HK | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% |
| Kimberly-Clark KMB | $65.8B | +11% | -8% | 14% | 15.2× | 5.1% |
| Procter & Gamble PG | $395B | +20% | +4% | 24% | 24.1× | 0.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1044.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.1% | +0.9% | 4th highest of 21 |
| 6-month return | -12.0% | +6.6% | 6th lowest of 21 |
| Distance from 52-week high | -23.5% | -20.6% | 10th lowest of 21 |
| Revenue growth (TTM) | +2.2% | +4.3% | 9th lowest of 21 |
| Operating margin | 11.2% | 11.2% | 11th highest of 21 |
| Forward P/E | 9.1× | 23.1× | 2nd cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -8.2% | 2.5% | 2nd least demanding of 17 |
| Growth delivered (Del g) | -0.1% | +10.2% | 4th lowest of 17 |
| Hurdle (Req g minus delivered) | -8.1 pp | -2.6 pp | 7th least demanding of 17 |
| ROIC minus cost of capital | +3.2 pp | +5.3 pp | 8th lowest of 19 |
| EV / EBITDA | 6.3× | 11.4× | 3rd cheapest of 17 |
| Net debt / EBITDA | -0.2× | -0.8× | 6th most indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Interparfums ITP.PA | France | $3.49B | +66% | -4% | 18% | 26.9× | 15.6% | +19.6% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% | +3.5% |
| Rohto Pharmaceutical 4527.T | Japan | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% | +13.7% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.67B | -8% | +32% | 31% | 14.3× | 4.1% | +41.1% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.91B | -23% | +9% | 28% | 32.4× | 31.1% | +4.5% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Cupid CUPID.NS | India | $5.22B | +218% | +125% | 33% | n/a | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |